Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Lonza to Host Mycoplasma Webinar

Cologne (Germany) / Walkersville, MD (USA), 23 February 2016 – Lonza has announced that it will host a free 60-minute webinar on 8 March 2016 titled “Mycoplasma – Uncover the Hidden Enemy in Cell Culture.” Mycoplasma contamination poses a considerable threat to cells in culture – and to the researcher it brings the potential loss […]

Read More »

HBA Metro presents: LinkedIn: What’s New? What’s Hot?

This webinar will help you understand what LinkedIn can and cannot do for you. You will learn about recent LinkedIn developments and how they can benefit your profile, and how to keep track of LinkedIn as it continues to evolve.

Read More »

J&J must pay $72 million for cancer death linked to talcum powder: lawyers

Johnson & Johnson (JNJ.N) was ordered by a Missouri state jury to pay $72 million of damages to the family of a woman whose death from ovarian cancer was linked to her use of the company’s talc-based Baby Powder and Shower to Shower for several decades. In a verdict announced late Monday night, jurors in […]

Read More »

FDA says PTC’s marketing application insufficient, shares slip

PTC Therapeutics Inc’s marketing application for its muscle disorder drug was not sufficient to merit a review, the U.S. Food and Drug Administration said, pushing the company’s stock down about 40 percent before the bell. PTC’s drug, translarna, is being evaluated in patients with Duchenne muscular dystrophy (DMD), a progressive degenerative disorder that hampers muscle […]

Read More »

Pronutria Biosciences Announces $42.5 Million Equity Investment from Nestlé Health Science

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Pronutria Biosciences Inc., a biotechnology company pioneering first-in-class medicines for serious conditions linked to amino acid imbalances, announced today that it has completed a $42.5 million investment by Nestlé Health Science. The proceeds from this financing will help to fund the ongoing rapid transformation of the company from a unique and revolutionary platform […]

Read More »

Authorities Raid Novartis AG Offices in Korea Over Bribery Allegations

Officials representing the Seoul Western District Prosecutors’ Office in South Korea raided the local offices of Switzerland-based Novartis AG (NVS), looking for evidence of bribery allegations.   According to the Yonhap News Agency, the Korean officials seized documents and account books on Monday around 9 a.m. local time. A Korean prosecution official said the raid […]

Read More »

IMS Health Increased Headcount by 4,800 in 2015

IMS Health Holdings reported an employee base numbering more than 15,000 people at the close of 2015, up from 10,200 a year earlier as the company absorbed business units of Cegedim it acquired for $426 million last April, as well as 14 smaller companies. Danbury-based IMS Health (NYSE: IMS) tracks pharmaceutical pricing and sales and […]

Read More »

Proof Eating Chocolate Makes Your Brain Work Better, University of South Australia Study

The Cognitive Benefits Of Eating Chocolate With Easter about a month away, it’s good news for chocolate lovers as new research has revealed that those who eat chocolate at least once per week performed better on multiple cognitive tasks, compared to those who ate chocolate less frequently. This research was undertaken by Dr Georgie Crichton, […]

Read More »

Bill Gates says Zika response better than for Ebola

The Bill and Melinda Gates Foundation has turned its attention to the Zika virus outbreak, and its founders said the response to the crisis, which may be linked to devastating birth defects in South America, has been better than for the 2014 Ebola outbreak in Africa. “We got deeply involved in Ebola, and we’re already […]

Read More »

FDA Accepts Sanofi New Drug Application for Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

PARIS, Feb. 22, 2016 /PRNewswire/ — Sanofi announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for its investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for the treatment of adults with type 2 diabetes. Following the redemption of a Priority Review […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom